IGF-1 Expressing Neural Stem Cells for Neurodegenerative Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering insulin-like growth factor-1 (IGF-1) to treat neurodegenerative diseases, such as ALS, have shown limited efficacy, particularly with subcutaneous administration in human clinical trials, highlighting the need for improved delivery methods that effectively target neuronal cell loss in the central nervous system.
Innovation Solution
Human neural stem cells stably expressing IGF-1 isoform 4 are used, which can engraft into the brain and spinal cord, differentiating into neurons and glia, and secreting the growth factor, thereby providing a therapeutic delivery of IGF-1 to sites of neuronal loss.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If subcutaneous administration of mature recombinant IGF-1 is used, then the treatment can be delivered to human patients, but it does not demonstrate efficacy in treating ALS
Solution Approach 1:
The patent uses neural stem cells as an intermediary vehicle to deliver IGF-1 directly to the CNS. Instead of administering mature recombinant IGF-1 systemically, the stem cells serve as living carriers that migrate to and engraft in the brain and spinal cord, locally secreting IGF-1 at the site of neuronal loss. This resolves the contradiction by providing both a deliverable formulation (stem cell transplant) and effective localized treatment.
Solution Approach 2:
The invention implements local quality by enabling IGF-1 secretion specifically at the site of neuronal cell loss in the CNS. The neural stem cells homing to affected areas and differentiating into neurons and glia ensure that IGF-1 is delivered precisely where needed, rather than systemic distribution. This localized delivery achieves therapeutic efficacy while maintaining ease of administration through targeted cell therapy.
2Reliability
If viral vectors are used to deliver IGF-1, then treatment shows promise in animal models, but the method complexity increases
Solution Approach 1:
The neural stem cells are genetically modified to contain the IGF-1 gene and autonomously produce and secrete IGF-1 after engraftment in the CNS. The cells serve themselves by continuously expressing the therapeutic protein without requiring external viral delivery mechanisms or repeated administrations. This self-sustaining approach maintains efficacy while reducing the complexity of the delivery system compared to viral vector methods.
3Productivity
If neural stem cells stably overexpress IGF-1 are used, then the number of GAD65-positive GABAergic neurons increases, but the cell engineering complexity increases
Solution Approach 1:
The patent merges two functions into a single cell type: neural stem cells are engineered to both differentiate into functional neurons (including GABAergic neurons) and simultaneously stably express IGF-1. This combination allows the same cell population to provide both structural replacement (neurons) and therapeutic factor delivery, achieving high productivity while managing engineering complexity through a unified cell platform.
Data Source
Figure 1A~1C
Figure 2A~2G
Figure 3A~3F
AI summary
The present disclosure provides a human neural stem cell comprising an exogenous polynucleotide coding for a growth factor such as IGF-1. Also disclosed are methods of using the human neural stem cells for the treatment of neurodegenerative diseases or disorders including, for example, ALS. The present disclosure generally relates to a human neural stem cell comprising an exogenous polynucleotide coding for a growth factor including, for example, a neurotrophic factor. In an embodiment, the growth factor is stably expressed by the human neural stem cell. Such human neural stem cells may be used for the treatment of a neurodegenerative disease or disorder in a subject in need thereof (e.g., a human subject having a neurodegenerative disease or disorder).